Efficacy of memantine compared with sodium valproate as prophylactic treatment for migraine: a controlled randomized pilot study
Damaris Vazquez-Guevara , Alejandro Orozco-Narvaez , Hector G. Hernandez-Rodriguez , Francisco Rivas-Ruvalcaba , Juan Manuel Shiguetomi-Medina , Ildefonso Rodriguez-Leyva
Exploration of Neuroprotective Therapy ›› 2023, Vol. 3 ›› Issue (2) : 131 -138.
Aim: To compare the efficacy of memantine with that of valproate as a prophylactic treatment for episodic migraine within three months. The efficacy, safety, and response rate were evaluated. Methods: Prospective, randomized, double-blind, controlled clinical trial randomized participants were divided into two groups. The memantine group received memantine 10 mg twice daily, and the valproate group received valproate 500 mg twice daily. Results: Thirty-three patients participated in the study; 27 completed the treatment protocol, 14 in the memantine group, and 13 in the valproate group. The mean number of migraine attacks per month in the memantine group was 5.31 [standard deviation (SD) ± 1.54] initially and 0.93 (SD ± 1.49) at the end of treatment, noting a decrease of 4.21 (SD ± 1.76; P < 0.001). In the valproate group, the mean number of migraine attacks per month was 5.35 (SD ± 1.11) initially and 0.77 (SD ± 1.16) at the end of treatment, with a difference of 4.5 (SD ± 1.39; P < 0.001). All 27 patients had excellent response rates. Adverse effects were infrequent and mild in severity. Conclusions: A clinical trial compared the efficacy of memantine with that of valproate (first-line drug) as a prophylactic treatment. A significant reduction in attacks was noted in both drugs. Memantine could be a new preventive treatment option for migraine (ClinicalTrials.gov identifier: NCT04698525).
Memantine / valproate / prophylactic treatment / episodic migraine / efficacy / safety
| [1] |
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018; 392: 1789-858. |
| [2] |
|
| [3] |
Schwedt TJ. Preventive therapy of migraine. Continuum (Minneap Minn). 2018; 24: 1052-65. |
| [4] |
|
| [5] |
Hepp Z, |
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018; 38: 1-211. |
| [13] |
|
| [14] |
Tonini MC. Gender differences in migraine. Neurol Sci. 2018; 39: 77-8. |
/
| 〈 |
|
〉 |